Evidence map›Paper›PMID 38671143›Full record

ArticleScientific reports2024

Agonist-selective activation of individual G-proteins by muscarinic receptors.

Dominik Nelic, Nikolai Chetverikov, Martina Hochmalová, Christina Diaz, Vladimír Doležal, John Boulos, Jan Jakubík, Kirill Martemyanov, Alena Janoušková-Randáková

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 0 citations in OpenAlex.

  1. Moving beyond 5-HTPsychopharmacology · 2026
    Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Dominik NelicDepartment of Neurochemistry, Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic.
Nikolai ChetverikovDepartment of Neurochemistry, Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic.
Martina HochmalováDepartment of Neurochemistry, Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic.
Christina DiazDepartment of Physical Sciences, Barry University, Miami Shores, Miami, FL, USA.
Vladimír DoležalDepartment of Neurochemistry, Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic.
John BoulosDepartment of Physical Sciences, Barry University, Miami Shores, Miami, FL, USA.
Jan JakubíkDepartment of Neurochemistry, Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic.
Kirill MartemyanovDepartment of Neuroscience, UF Scripps Biomedical Research, University of Florida, Jupiter, FL, 33458, USA. kmartemyanov@ufl.edu.
Alena Janoušková-RandákováDepartment of Neurochemistry, Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic. alena.janouskova@fgu.cas.cz.
Czech Academy of Sciences, Institute of Physiology · CZBarry University · USCzech Academy of Sciences · CZUniversity of Florida · US

Funding

European Union Next Generation EU Programme EXCELES, LX22NPO5104Grantová Agentura České Republiky 19-06106Y
6 · The paper itself

Abstract

Selective activation of individual subtypes of muscarinic receptors is a promising way to safely alleviate a wide range of pathological conditions in the central nervous system and the periphery as well. The flexible G-protein interface of muscarinic receptors allows them to interact with several G-proteins with various efficacy, potency, and kinetics. Agonists biased to the particular G-protein mediated pathway may result in selectivity among muscarinic subtypes and, due to the non-uniform expression of individual G-protein alpha subunits, possibly achieve tissue specificity. Here, we demonstrate that novel tetrahydropyridine-based agonists exert specific signalling profiles in coupling with individual G-protein α subunits. These signalling profiles profoundly differ from the reference agonist carbachol. Moreover, coupling with individual Gα induced by these novel agonists varies among subtypes of muscarinic receptors which may lead to subtype selectivity. Thus, the novel tetrahydropyridine-based agonist can contribute to the elucidation of the mechanism of pathway-specific activation of muscarinic receptors and serve as a starting point for the development of desired selective muscarinic agonists.

Indexed as

Muscarinic AgonistsReceptors, MuscarinicAnimalsCarbacholCHO CellsCricetulusGTP-Binding Protein alpha SubunitsGTP-Binding ProteinsHumansPyridinesSignal TransductionCarbacholGTP-Binding Protein alpha SubunitsGTP-Binding ProteinsMuscarinic AgonistsPyridinesReceptors, Muscarinic

Identifiers

PMID38671143
PMCPMC11053168
OpenAlexW4395677093

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.